MX2022006892A - Compuesto agonista del receptor sensor de calcio y aplicación del mismo. - Google Patents

Compuesto agonista del receptor sensor de calcio y aplicación del mismo.

Info

Publication number
MX2022006892A
MX2022006892A MX2022006892A MX2022006892A MX2022006892A MX 2022006892 A MX2022006892 A MX 2022006892A MX 2022006892 A MX2022006892 A MX 2022006892A MX 2022006892 A MX2022006892 A MX 2022006892A MX 2022006892 A MX2022006892 A MX 2022006892A
Authority
MX
Mexico
Prior art keywords
calcium
application
sensing receptor
agonist compound
receptor agonist
Prior art date
Application number
MX2022006892A
Other languages
English (en)
Spanish (es)
Inventor
Jin Zhang
Lei Wang
Fei Gao
Cheng Liao
Fangzhou Wu
Ran Wu
Original Assignee
Beijing Tuo Jie Biopharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Tuo Jie Biopharmaceutical Co Ltd filed Critical Beijing Tuo Jie Biopharmaceutical Co Ltd
Publication of MX2022006892A publication Critical patent/MX2022006892A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
MX2022006892A 2019-12-09 2020-12-08 Compuesto agonista del receptor sensor de calcio y aplicación del mismo. MX2022006892A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201911250088 2019-12-09
PCT/CN2020/134598 WO2021115272A1 (zh) 2019-12-09 2020-12-08 钙敏感受体激动剂化合物及其应用

Publications (1)

Publication Number Publication Date
MX2022006892A true MX2022006892A (es) 2022-10-07

Family

ID=76328843

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006892A MX2022006892A (es) 2019-12-09 2020-12-08 Compuesto agonista del receptor sensor de calcio y aplicación del mismo.

Country Status (11)

Country Link
US (1) US20230041996A1 (cg-RX-API-DMAC7.html)
EP (1) EP4091623A4 (cg-RX-API-DMAC7.html)
JP (1) JP7796013B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220110789A (cg-RX-API-DMAC7.html)
CN (2) CN118496313A (cg-RX-API-DMAC7.html)
AU (1) AU2020399030B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022011127A2 (cg-RX-API-DMAC7.html)
CA (1) CA3159744A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022006892A (cg-RX-API-DMAC7.html)
TW (1) TW202122410A (cg-RX-API-DMAC7.html)
WO (1) WO2021115272A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117295510A (zh) * 2021-06-08 2023-12-26 北京拓界生物医药科技有限公司 一种钙敏感受体激动剂的组合物及其应用
TW202313655A (zh) * 2021-06-08 2023-04-01 大陸商北京拓界生物醫藥科技有限公司 鈣敏感受體激動劑化合物的鹽酸鹽及醫藥組成物和其應用
CN121378400A (zh) * 2024-10-24 2026-01-23 成都诺和晟泰生物科技有限公司 一种多肽化合物、包含其的组合物及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20050460A1 (es) * 2003-04-23 2005-07-08 Japan Tobacco Inc COMPUESTOS HETEROCICLICOS COMO ANTAGONISTAS CaSR (RECEPTOR SENSIBLE AL CALCIO)
EP2459208B1 (en) * 2009-07-29 2016-09-28 Kai Pharmaceuticals, Inc. Therapeutic agents for reducing parathyroid hormone levels
CN103270018A (zh) * 2010-11-26 2013-08-28 利奥制药有限公司 钙敏感受体激活化合物
WO2012069421A1 (en) * 2010-11-26 2012-05-31 Leo Pharma A/S Calcium-sensing receptor-active compounds
PT2717896T (pt) * 2011-06-08 2016-12-23 Kai Pharmaceuticals Inc Agentes terapêuticos para a regulação do fósforo sérico
MX355063B (es) * 2011-11-10 2018-04-04 Kai Pharmaceuticals Inc Calcimiméticos y métodos para su uso.

Also Published As

Publication number Publication date
US20230041996A1 (en) 2023-02-09
AU2020399030A1 (en) 2022-06-23
KR20220110789A (ko) 2022-08-09
EP4091623A1 (en) 2022-11-23
CN114222578B (zh) 2024-06-25
CN118496313A (zh) 2024-08-16
TW202122410A (zh) 2021-06-16
EP4091623A4 (en) 2024-01-03
CA3159744A1 (en) 2021-06-17
WO2021115272A1 (zh) 2021-06-17
BR112022011127A2 (pt) 2022-08-23
CN114222578A (zh) 2022-03-22
JP7796013B2 (ja) 2026-01-08
AU2020399030B2 (en) 2026-04-09
JP2023504904A (ja) 2023-02-07

Similar Documents

Publication Publication Date Title
ZA202508806B (en) Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
IL287004A (en) Dosage forms and regimens for amino acid compounds
PH12018501099A1 (en) Novel biphenyl compound or salt thereof
CL2021003018S1 (es) Porción de dispositivo para administración de dosis. (divisional solicitud 200003174)
PH12022550343A1 (en) Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents
MY208377A (en) Compounds
BR112022011127A2 (pt) Composto agonista do receptor de detecção de cálcio e aplicação do mesmo
JOP20180113A1 (ar) مركبات ,تركيبات وطرق
MY199779A (en) Pyrrolopyrimidine compound and use thereof
MX2022008487A (es) Degradadores de smarca2-vhl.
CY1118388T1 (el) Θεραπευτικοι παραγοντες για τη μειωση των επιπεδων παραθορμονης
MX2021010870A (es) Bloqueadores de canales ionicos cargados y metodos de uso.
PH12020550616A1 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
CR20160243A (es) Composición herbicida sinérgica para el control de malezas a partir de combinaciones de 2,4-d-colina, glifosato y glufosinato
MX2020002430A (es) Compuestos inhibidores del receptor 1 del acido lisofosfatidico (lpar1).
WO2015114395A9 (en) Process for the preparation of vortioxetine salts
CU20210099A7 (es) Anticuerpos de receptor de péptido natriurético 1
NZ703347A (en) Use of 2-methylene-19-nor-(20s)-1α,25-dihydroxyvitamin d3 to treat secondary hyperparathyroidism
EP4000086A4 (en) Ion implantation system with mixture of arc chamber materials
MX2024015245A (es) Compuestos utiles como moduladores de la autofagia mediada por chaperonas
MX2022005813A (es) Formas de dosificacion novedosas de rofecoxib y métodos relacionados.
CL2022001317A1 (es) Composición farmacéutica oral que comprende compuesto de carbamato y método de preparación para la misma.
MX395521B (es) Formulaciones farmacéuticas de liberación retardada que comprenden ácido valproico y usos de estas
WO2020016302A8 (en) A xinafoate salt of a jak inhibiting compound
ZA202204251B (en) Compounds and compositions for the treatment of parasitic diseases